Abstract
Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Retroviral Agents / economics
-
Anti-Retroviral Agents / therapeutic use*
-
Clinical Trials as Topic / ethics*
-
Developing Countries
-
Financing, Organized / ethics
-
Financing, Organized / methods
-
HIV Infections / drug therapy
-
HIV Infections / economics
-
HIV Infections / prevention & control*
-
HIV Seropositivity / drug therapy
-
Health Care Costs / ethics
-
Health Services Accessibility / ethics
-
Humans